Nuvation Bio (NUVB)

Executive Summary

Nuvation Bio is a global oncology company developing innovative small molecules to address high-unmet-need cancers. Its lead asset, taletrectinib, is a next-generation ROS1/NTRK inhibitor currently in a Phase 3 trial (NCT07154706) for ROS1-positive non-small cell lung cancer (NSCLC). The drug has shown promising efficacy and safety in earlier studies, with potential to overcome resistance to first-generation TKIs. Another key pipeline candidate is safusidenib, a mutant IDH1 inhibitor in Phase 3 for IDH1-mutant glioma (NCT05303519), targeting a genetically defined subset of gliomas with no approved targeted therapies. Both programs are recruiting, and the company is also exploring earlier-stage assets such as NUV-422 (CDK2/4/6 inhibitor) for various tumors, though this program was terminated. With no approved products yet, Nuvation Bio's near-term value hinges on successful Phase 3 readouts and potential regulatory filings. Financially, the company is publicly traded (NYSE: NUVB) with a market cap of approximately $1.7B, reflecting investor optimism around its pipeline. Key upcoming catalysts include data updates from ongoing registrational trials, which could drive significant share price appreciation if positive.

Upcoming Catalysts (preview)

• Q1 2028Taletrectinib Phase 3 TRUST trial interim efficacy analysis in ROS1+ NSCLC65% success
• 2027Safusidenib Phase 3 pivotal trial data in IDH1-mutant glioma60% success
• H2 2026Potential partnership or licensing deal for taletrectinib outside the U.S.50% success